临床药师参与布鲁菌感染性心内膜炎1例治疗实践及分析  

One Case of Participation of Clinical Pharmacists in Treatment of Brucella Endocarditis

作　　者：余雄杰[1] 张静[1] 李园[1] 王鹏[1] 黄年旭[1] 陈锦华[1] YU Xiongjie;ZHANG Jing;LI Yuan;WANG Peng;HUANG Nianxu;CHEN Jinhua(Wuhan A sia Heart Hospital,Wuhan Hubei 430022,China)

机构地区：[1]武汉亚洲心脏病医院,湖北武汉430022

出　　处：《中国药物警戒》2020年第12期930-933,共4页Chinese Journal of Pharmacovigilance

基　　金：武汉市卫生计生委科研项目(WX18D35):PDCA循环管理法对降低抗菌药物使用强度的干预研究。

摘　　要：目的探讨临床药师在布鲁菌感染性心内膜炎患者治疗中的作用。方法临床药师依靠药学专业知识,参与抗感染治疗、药品不良反应处置及抗凝治疗等过程,协助医师制定优化的药物治疗方案。结果医师采纳临床药师建议,患者病情得到有效控制。结论临床药师参与临床药物治疗实践,可以更好地促进临床合理用药,保障患者用药安全。Objective To investigate the role of clinical pharmacists in the treatment of infective endocarditis with brucella.Methods Clinical pharmacists,using their pharmaceutical expertise,participated in the process of anti-infection treatment,adverse reaction disposal and anticoagulant treatment of one patient while assisting physicians in formulating optimal drug treatment programs.Results The clinicians took the advice of clinical pharmacists,and the patients'condition was effectively controlled.Conclusion T he participation of clinical pharmacists in clinical drug therapy can better promote rational clinical drug use and ensure the safety of drug use for patients.

关 键 词：布鲁菌病 心内膜炎 临床药师 药学监护 

分 类 号：R969.3[医药卫生—药理学]